Basilea valuation report "Return to anti-infectives and profits"

Sunday, December 4, 2022 @ 12:00 am

Basilea is well on track to deliver on its new strategy to become a pure-play anti-invectives R&D company with sustainable profits from 2023 onwards. Currently, revenues are primarily driven by Cresemba. Zevtera’s revenues should get a considerable boost upon launch in the lucrative US market.

Key catalysts include:

1. Cresemba approval in Japan (Q4 2022)
2. Repayment 2022 convertible bond (December 2022)
3. US filing of Zevtera for severe bacterial infections (around year-end 2022)

Basilea Valuation Report

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

Alithea Genomics secures loan from Swiss Technology Fund

Alithea Genomics, a leader in large-scale RNA sequencing, received a loan guarantee from Switzerland's Technology Fund, aiding its growth. The fund, part of the Swiss Federal Office for the Environment, supports companies reducing greenhouse gas emissions. Alithea's innovative technologies, such as BRB-seq and DRUG-seq, cut costs, time, and resource use in RNA sequencing, promoting sustainability.
September 24, 2024

Swiss innovators champion industrial biotech: Focus on flexibility, market diversity, and environmental impact

Industrial biotechnology promotes more energy-efficient and sustainable manufacturing processes as well as creating opportunities for reducing pollution, reusing waste and creating new products. It underpins a circular economy and a more sustainable chemicals industry which prioritizes protecting scarce natural resources. New bio-based products and processes have far-reaching and disruptive impact

Mabylon receives over CHF 1.3 million research grants from Innosuisse, Target ALS and ALS Association

Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.
September 24, 2024

ten23 health opens sterile manufacturing facility in Visp

ten23 health, a leading Swiss contract development and manufacturing organization (CDMO), yesterday proudly hosted the Grand Opening of its VIVA2 facility in Visp, Switzerland.
September 24, 2024

Azafaros presented positive study data for treatment of Niemann-Pick disease and Gangliosidosis

Azafaros has announced that data from the ongoing double-blind, placebo-controlled Phase 2 RAINBOW study investigating its lead asset, nizubaglustat in patients with Niemann-Pick disease type C (NPC) or GM2 gangliosidosis, were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal.
September 18, 2024